首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients
【24h】

Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients

机译:基于肿瘤肾细胞癌患者肿瘤内免疫细胞浸润的基于肿瘤内免疫细胞浸润的二分性免疫亚型的鉴定与验证

获取原文
           

摘要

Background Increasing evidence has elucidated the clinical significance of tumor infiltrating immune cells in predicting outcomes and therapeutic efficacy. In this study, we comprehensively analyze the tumor microenvironment (TME) immune cell infiltrations in clear cell renal cell carcinoma (ccRCC) and correlated the infiltration patterns with anti-tumor immunity and clinical outcomes. Methods We analyzed immune cell infiltrations in four independent cohorts, including the KIRC cohort of 533 patients, the Zhongshan ccRCC cohorts of 259 patients, the Zhongshan fresh tumor sample cohorts of 20 patients and the Zhongshan metastatic ccRCC cohorts of 87 patients. Intrinsic patterns of immune cell infiltrations were evaluated for associations with clinicopathological characteristics, underlying biological pathways, genetic changes, oncological outcomes and treatment responses. Results Unsupervised clustering of tumor infiltrating immune cells identified two microenvironment subtypes, TMEcluster-A and TMEcluster-B. Gene markers and biological pathways referring to immune evasion were upregulated in TMEcluster-B. TMEcluster-B associated with poor overall survival (p0.001; HR 2.629) and recurrence free survival (p=0.012; HR 1.870) in ccRCC validation cohort. TMEcluster-B cases had worse treatment response (p=0.009), overall survival (p0.001; HR 2.223) and progression free survival (p=0.015; HR 2.7762) in metastatic ccRCC cohort. The predictive accuracy of International Metastatic Database Consortium risk score was improved after incorporation of TME clusters. Conclusions TMEcluster-A featured increased mast cells infiltration, prolonged survival and better treatment response. TMEcluster-B was a heavily infiltrated but immunosuppressed phenotype enriched for macrophages, CD4 T cells, Tregs, CD8 T cells and B cells. TMEcluster-B predicted dismal survival and worse treatment response in clear cell renal cell carcinoma patients.
机译:背景技术越来越多的证据已经阐明了肿瘤渗透免疫细胞在预测结果和治疗效果方面的临床意义。在这项研究中,我们全面分析了透明细胞肾细胞癌(CCRCC)中的肿瘤微环境(TME)免疫细胞浸润,并将渗透模式与抗肿瘤免疫和临床结果相关联。方法采用四个独立队列分析免疫细胞浸润,包括脊髓群患者,中山CCRCC队患者,中山新鲜肿瘤样品群20例,中山转移性CCRCC队列87例。评估免疫细胞浸润的固有模式,用于临床病理特征,潜在的生物途径,遗传变化,肿瘤性能和治疗反应的缔合。结果肿瘤渗透免疫细胞的未经监督聚类鉴定了两种微环境亚型,TMECLUSTER-A和TMECLUSTER-B。在TMeCluster-B中上调了基因标记和引起免疫逃避的生物途径。 TMeCluster-B与CCRCC验证队列中的差的整体存活差(P <0.001; HR 2.629)和复发自由存活(P = 0.012; HR 1.870)。 TMeCluster-B病例的治疗反应较差(p = 0.009),总存活(P <0.001; HR 2.223)和逐步存活(P = 0.015; HR 2.7762)在转移性CCRCC队列中。在纳入TME集群后,改善了国际转移数据库联盟风险评分的预测准确性。结论TMECLUSTER-A具有较高的桅杆细胞浸润,延长存活率和更好的治疗反应。 TmeCluster-B是一种富含巨噬细胞,CD4 T细胞,Tregs,CD8 T细胞和B细胞的重染性但免疫抑制的表型。 TMECLUSTER-B预测透明细胞肾细胞癌患者的令人沮丧的存活和较差的治疗反应。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号